4. Juni 2018

Breakfast Brief with Univ.-Prof. Dr. Shahrokh F. Shariat

Univ.-Prof. Dr. Shahrokh F. Shariat, Chairman at the Department of Urology, Medical University Vienna, presents the most relevant urothelial carcinoma studies of ASCO Congress 2018.

The following abstracts are discussed:

Source: ASCO Annual Meeting 2018

  • Abstract 4535:

    Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.


  • Abstract 4506:

    A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).


  • Abstract 4507

    Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.


  • Abstract LBA 1509:

    Pan-cancer microsatellite instability to predict for presence of Lynch syndrome.


  • Abstract 4503:

    First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).


  • Abstract 4513:

    Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.


  • Abstract 4505:

    Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).


  • Abstract 4504:

    Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).


  • Dieser Beitrag erschien auch im Printmagazin krebs:hilfe!